Table 2.
Methodological quality evaluation.
| Authors | Design | Representatives of Exposed Cohort | Selection of Nonexposed Cohort | Ascertainment of Exposure | Assesment of Outcome | Length Follow-Up |
| Hellinger S et al22 | ● | ● | ● | ●● | ●● | ● |
| Tacconi L et al13 | ● | ● | ● | ●● | ●● | |
| Kyung-Hoon K et al14 | ● | ● | ||||
| Hahn P et al23* | ● | ●● | ● | |||
| Heo DH et al24 | ● | ● | ●● | ● | ||
| Siu CK et al25 | ●● | ● | ●● | ● | ● | |
| Oertel JM et al26 | ● | ● | ● | ●● | ●● | |
| Bruder M et al27 | ●● | ● | ●● | ● | ● | |
| Denis DR et al2 | ●● | ● | ●● | ● | ||
| Birch BD et al28 | ● | ● | ● | ● | ||
| Eshraghi Y et al7 | ● | ● | ● | ● | ||
| Zhenbo Z et al29 | ● | ● | ●● | ●● | ● | |
| Alimi M et al30 | ●● | ● | ●● | ●●● | ● | |
| Sukkarieh HG et al31 | ● | ● | ●● | ●● | ||
| Knafo S et al32 | ● | ● | ● | |||
| Komp M et al33 | ● | ●● | ● | ●● | ●●● | |
| Ortiz O et al51 | ● | ● | ● | |||
| Cambron SC et al11 | ●● | ●● | ● | |||
| Ganau M et al3 | ● | ● | ● | ● | ||
| Ha SW et al35 | ● | ● | ●● | ● | ||
| James A et al36 | ● | ● | ●● | |||
| Amoretti N et al11 | ●● | ● | ●● | ●● | ||
| Landi A et al37 | ● | ● | ●● | ● | ||
| Schulz M et al16 | ● | ● | ● | ● | ||
| El Shazly A et al38 | ● | ● | ● | ● | ||
| Matsumoto M et al39 | ● | ● | ● | ● | ● | |
| Xu R et al40 | ●● | ●● | ||||
| Allen TL et al10 | ● | ● | ●● | ●●● | ||
| Martha JF et al9 | ● | ● | ●● | ● | ||
| Terao T et al41 | ● | ● | ● | ● | ||
| Weiner BK et al39 | ● | ● | ●● | |||
| Sehati N et al43 | ● | ●● | ● | |||
| Acharya R et al1 | ● | ● | ● | |||
| Metellus P et al44 | ●● | ● | ● | ● | ||
| Deinsberger R et al15 | ● | ● | ● | ● | ||
| Sandhu FA et al45 | ● | ●● | ● | |||
| Epstein NE et al46 | ●● | ● | ●● | |||
| Pirotte B et al47 | ● | ● | ● | ● | ||
| Bureau NJ et al12 | ● | ● | ● | |||
| Salmon B et al48 | ● | ● | ● | ● | ||
| Banning CS et al46 | ● | ● | ● | ● | ||
| Trummer M et al49 | ● | ● | ● | ● | ||
| Lyons MK et al50 | ●● | ● | ● | ● |
Design: One dot for prospective or randomized controlled trials. Representatives of exposed cohort: One dot for study reporting detailed inclusion criteria, two dots for studies reporting detailed inclusion and exclusion criteria. Selection of non-exposed cohort: One dot for each study reporting a control group. Ascertainment of exposure: One dot for the authors confirming the intraoperative presence of a JFC, two dots if the histological confirmation was reported and an accurate JFC description provided. Assesment of outcome: One dot for each different clinical score utilized by authors for measuring postoperative outcomes. Length of follow-up: One dot if the follow-up was more than 24 months.